Strategic area of application
Human Medicine
Application market
Cardiology - Immune, AutoIm & Inflam. diseases - Infectiology - Parasitology
Activities
CRO
Technologies
Design & Modelling studies - Others
Presentation of company's activity
Cynbiose is a company meeting the needs of public and private companies involved in drug development and biomedical research.Whereas larger CROs already propose standard regulatory studies, Cynbiose is one of the rare European private companies with expertise in primatology, which carries out exploratory studies with the aim to reduce time of drug development. Cynbiose allows private and academic researchers to access NHP models with support to face high level of constraints due to the use of this sensitive animal model (regulatory, sanitary, technical, ethical and economical aspects).Cynbiose collaborates with strategic partners dedicated to the use of NHP in research: i) the testing facilities are located at the Institut Claude Bourgelat at the National Veterinary School of Lyon (VetAgeo Sup, Marcy l'étoile); ii) Bioprim (Bazièges, France) is the only one private company in France dedicated to the import and quarantine of NHP for research with high sanitary controls; iii) breeding colonies supply the NHP with high quality standards.Cynbiose is also supported by different scientific experts for the development of innovative protocols on NHP.Cynbiose is also member of the world-class competitiveness cluster “Lyon Biopôle”, to set-up scientific collaborations with national and international companies.
Key features of company
- Animal facility with a high capacity (100 animals of different reliable NHP species) - Biosafety level 1, 2 and 3.- Expertise- Flexibility and Reactivity- Strategic Partners- Innovative Models developed in partnership- Science, Quality and Animal Welfare AAALAC International accrédités in 2015 - Good Laboratory Practices certified by french authorities AFSSAPS in december 2011
Recent news
Research and development programs in progress since 2009:
·Rheumatology: NHP model for osteoarthritis and osteoporosis.·Pharmacology of the CNS: assessment of the crossing of the blood-brain barrier.·Cardiovascular diseases: A chronic post ischaemic heart failure model in cynomolgus monkeys.·Infectious diseases: -NHP model for Malaria. -NHP model for RSV.
GLP since 2011
AAALAC since 2015
Skills and know-how
-Expertise in NHP models from import, quarantine, housing, ethical, sanitary, technical and veterinary aspects to the development of protocols and data analyses.-Innovative NHP based on the used of innovative technologies (imaging, telemetry, video-monitoring).-Good Laboratory Practices accredited to perform toxicological and pharmacokinetic studies.-Focused on ethics
Higlights
Pharmacological models: rhumatology, cardiovascular and neurovascular diseases, inflammatory diseases, infectious diseases respiratory diseases and metabolic diseases
Product pipeline 1
Therapeutic area: Rheumatology
Therapeutic indication: Arthrosis
Preclinical: Primate modèle for arthrosis
Product pipeline 2
Therapeutic area: Cardiovascular
Therapeutic indication: Ischemia
Preclinical: An accute and chronic primate model of myocardial ischemia
Product pipeline 3
Therapeutic area: Inflammatory diseases
Preclinical: A primate model of multiple sclerosis, psoriasis, DTH, skin graft
